Blood-based microRNAs as Potential Diagnostic Biomarkers for Melanoma: A Meta-Analysis


Цитировать

Полный текст

Аннотация

Introduction:Circulating microRNAs (miRNAs) serve as noninvasive diagnostic markers in many cancers. This meta-analysis aims to evaluate the diagnostic efficacy of circulating microRNAs for melanoma.

Material and Methods:The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and ROC curve were evaluated using the Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.3.3 software packages. To investigate the heterogeneity, the I2 and Chi-square tests were used. The publishing bias was evaluated using Begg’s rank correlation and Egger regression asymmetry tests.

Results:A total of 9 articles covering 13 studies (more than 50 miRs individually and in combination) were included, containing 1,355 participants (878 cases and 477 controls). The overall pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio (DOR), and AUC were 0.78 (95% CI: 0.76-0.81), 0.80 (95% CI: 0.77-0.83), 4.32 (95% CI: 3.21-5.82), 0.17 (95% CI: 0.09-0.32), 28.0 (95% CI: 15.34-51.09), and 0.91, respectively. According to Begg's and Egger's tests, there was no publication bias (Begg's p = 0.160 and Egger's p = 0.289).

Conclusion:Circulating miRNAs can serve as fair and non-invasive diagnostic biomarkers for melanoma. Additionally, specific miRNAs still need to be discovered for diagnosing melanoma.

Об авторах

AmirHossein Aalami

Department of Nutrition and Integrative Physiology, College of Health, University of Utah

Автор, ответственный за переписку.
Email: info@benthamscience.net

Hossein Abdeahad

Department of Nutrition and Integrative Physiology, College of Health, University of Utah

Email: info@benthamscience.net

Ali Mokhtari

Department of Biology, Islamic Azad University

Email: info@benthamscience.net

Farnoosh Aalami

Student Research Committee, North Khorasan University of Medical Sciences

Email: info@benthamscience.net

Amir Amirabadi

Department of Internal Medicine, Mashhad Medical Sciences Branch, Islamic Azad University

Email: info@benthamscience.net

Ehsan Aliabadi

Biochemical Research Center, Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad

Email: info@benthamscience.net

Omid Pirzade

Department of English Language and Literature, Faculty of Literature and Humanities, Hakim Sabzevari University

Email: info@benthamscience.net

Amirhossein Sahebkar

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences

Автор, ответственный за переписку.
Email: info@benthamscience.net

Список литературы

  1. Woźniak, M.; Nowak, M.; Lazebna, A.; Więcek, K.; Jabłońska, I.; Szpadel, K.; Grzeszczak, A.; Gubernator, J.; Ziółkowski, P. The comparison of in vitro photosensitizing efficacy of curcumin-loaded liposomes following photodynamic therapy on melanoma MUG-Mel2, squamous cell carcinoma SCC-25, and normal keratinocyte HaCaT cells. Pharmaceuticals, 2021, 14(4), 374. doi: 10.3390/ph14040374 PMID: 33920669
  2. Cullen, J.K.; Simmons, J.L.; Parsons, P.G.; Boyle, G.M. Topical treatments for skin cancer. Adv. Drug Deliv. Rev., 2020, 153, 54-64. doi: 10.1016/j.addr.2019.11.002 PMID: 31705912
  3. Nehal, K.S.; Bichakjian, C.K. Update on keratinocyte carcinomas. N. Engl. J. Med., 2018, 379(4), 363-374. doi: 10.1056/NEJMra1708701 PMID: 30044931
  4. Haggenmüller, S.; Maron, R.C.; Hekler, A.; Utikal, J.S.; Barata, C.; Barnhill, R.L.; Beltraminelli, H.; Berking, C.; Betz-Stablein, B.; Blum, A.; Braun, S.A.; Carr, R.; Combalia, M.; Fernandez-Figueras, M.T.; Ferrara, G.; Fraitag, S.; French, L.E.; Gellrich, F.F.; Ghoreschi, K.; Goebeler, M.; Guitera, P.; Haenssle, H.A.; Haferkamp, S.; Heinzerling, L.; Heppt, M.V.; Hilke, F.J.; Hobelsberger, S.; Krahl, D.; Kutzner, H.; Lallas, A.; Liopyris, K.; Llamas-Velasco, M.; Malvehy, J.; Meier, F.; Müller, C.S.L.; Navarini, A.A.; Navarrete-Dechent, C.; Perasole, A.; Poch, G.; Podlipnik, S.; Requena, L.; Rotemberg, V.M.; Saggini, A.; Sangueza, O.P.; Santonja, C.; Schadendorf, D.; Schilling, B.; Schlaak, M.; Schlager, J.G.; Sergon, M.; Sondermann, W.; Soyer, H.P.; Starz, H.; Stolz, W.; Vale, E.; Weyers, W.; Zink, A.; Krieghoff-Henning, E.; Kather, J.N.; von Kalle, C.; Lipka, D.B.; Fröhling, S.; Hauschild, A.; Kittler, H.; Brinker, T.J. Skin cancer classification via convolutional neural networks: Systematic review of studies involving human experts. Eur. J. Cancer, 2021, 156, 202-216. doi: 10.1016/j.ejca.2021.06.049 PMID: 34509059
  5. Shi, X.; Zhou, Q.; Huang, B.; Xia, S.; Jiang, Y.; Fang, S.; Lin, J. Prognostic and immune-related value of STK17B in skin cutaneous melanoma. PLoS One, 2022, 17(2), e0263311. doi: 10.1371/journal.pone.0263311 PMID: 35171924
  6. Liu, C.; Liu, Y.; Yu, Y.; Zhao, Y.; Yu, A. Comprehensive analysis of ferroptosis-related genes and prognosis of cutaneous melanoma. BMC Med. Genomics, 2022, 15(1), 39. doi: 10.1186/s12920-022-01194-z PMID: 35232428
  7. Viale, P.H. The American Cancer Society’s facts & figures: 2020 edition. J. Adv. Pract. Oncol., 2020, 11(2), 135-136. PMID: 33532112
  8. Keyghobadi, N.; Rafiemanesh, H.; Mohammadian-Hafshejani, A.; Enayatrad, M.; Salehiniya, H. Epidemiology and trend of cancers in the province of Kerman: Southeast of Iran. Asian Pac. J. Cancer Prev., 2015, 16(4), 1409-1413. doi: 10.7314/APJCP.2015.16.4.1409 PMID: 25743807
  9. Ma, Y.; Qu, S.; Xu, L.; Lu, H.; Li, B. An in vitro study of the effect of 5-ALA-mediated photodynamic therapy on oral squamous cell carcinoma. BMC Oral Health, 2020, 20(1), 258. doi: 10.1186/s12903-020-01239-8 PMID: 32938451
  10. Akasov, R.A.; Sholina, N.V.; Khochenkov, D.A.; Alova, A.V.; Gorelkin, P.V.; Erofeev, A.S.; Generalova, A.N.; Khaydukov, E.V. Photodynamic therapy of melanoma by blue-light photoactivation of flavin mononucleotide. Sci. Rep., 2019, 9(1), 9679. doi: 10.1038/s41598-019-46115-w PMID: 31273268
  11. Trager, M.H.; Geskin, L.J.; Samie, F.H.; Liu, L. Biomarkers in melanoma and non-melanoma skin cancer prevention and risk stratification. Exp. Dermatol., 2022, 31(1), 4-12. doi: 10.1111/exd.14114 PMID: 32415889
  12. Al Bitar, S.; Ballouz, T.; Doughan, S.; Gali-Muhtasib, H.; Rizk, N. Potential role of micro ribonucleic acids in screening for anal cancer in human papilloma virus and human immunodeficiency virus related malignancies. World J. Gastrointest. Pathophysiol., 2021, 12(4), 59-83. doi: 10.4291/wjgp.v12.i4.59 PMID: 34354849
  13. Fathullahzadeh, S.; Mirzaei, H.; Honardoost, M.A.; Sahebkar, A.; Salehi, M. Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther., 2016, 23(10), 327-332. doi: 10.1038/cgt.2016.34 PMID: 27659777
  14. Mirzaei, H.; Sahebkar, A.; Mohammadi, M.; Yari, R.; Salehi, H.; Jafari, M.; Namdar, A.; Khabazian, E.; Jaafari, M.; Mirzaei, H. Circulating micrornas in hepatocellular carcinoma: Potential diagnostic and prognostic biomarkers. Curr. Pharm. Des., 2016, 22(34), 5257-5269. doi: 10.2174/1381612822666160303110838 PMID: 26935703
  15. Raji, S.; Sahranavard, M.; Mottaghi, M.; Sahebkar, A. MiR-212 value in prognosis and diagnosis of cancer and its association with patient characteristics: A systematic review and meta-analysis. Cancer Cell Int., 2022, 22(1), 163. doi: 10.1186/s12935-022-02584-0 PMID: 35473623
  16. Aalami, A.H.; Abdeahad, H.; Mesgari, M.; Sahebkar, A. MicroRNA-223 in gastrointestinal cancers: A systematic review and diagnostic meta-analysis. Eur. J. Clin. Invest., 2021, 51(2), e13448. doi: 10.1111/eci.13448 PMID: 33244751
  17. Aalami, A.H.; Abdeahad, H.; Shoghi, A.; Mesgari, M.; Amirabadi, A.; Sahebkar, A. Brain tumors and circulating micrornas: A systematic review and diagnostic meta-analysis. Expert Rev. Mol. Diagn., 2022, 22(2), 201-211. doi: 10.1080/14737159.2022.2019016 PMID: 34906021
  18. Aalami, A.H.; Mesgari, M.; Sahebkar, A. Synthesis and characterization of green zinc oxide nanoparticles with antiproliferative effects through apoptosis induction and microRNA modulation in breast cancer cells. Bioinorganic chemistry and applications, 2020, 2020
  19. Aalami, A.H.; Abdeahad, H.; Aalami, F.; Amirabadi, A. Can microRNAs be utilized as tumor markers for recurrence following nephrectomy in renal cell carcinoma patients? A meta-analysis provides the answer. Urologic oncology, 2023, 41(1), 52-e1-. e10.
  20. Aalami, A.H.; Hoseinzadeh, M.; Hosseini Manesh, P.; Jiryai Sharahi, A.; Kargar Aliabadi, E. Carcinogenic effects of heavy metals by inducing dysregulation of microRNAs: A review. Mol. Biol. Rep., 2022, 49(12), 12227-12238. doi: 10.1007/s11033-022-07897-x PMID: 36269534
  21. Goradel, N.H.; Mohammadi, N.; Haghi-Aminjan, H.; Farhood, B.; Negahdari, B.; Sahebkar, A. Regulation of tumor angiogenesis by microRNAs: State of the art. J. Cell. Physiol., 2019, 234(2), 1099-1110. doi: 10.1002/jcp.27051 PMID: 30070704
  22. Ahadi, A. Dysregulation of miRNAs as a signature for diagnosis and prognosis of gastric cancer and their involvement in the mechanism underlying gastric carcinogenesis and progression. IUBMB Life, 2020, 72(5), 884-898. doi: 10.1002/iub.2259 PMID: 32078236
  23. Ghafouri-Fard, S.; Vafaee, R.; Shoorei, H.; Taheri, M. MicroRNAs in gastric cancer: Biomarkers and therapeutic targets. Gene, 2020, 757, 144937. doi: 10.1016/j.gene.2020.144937 PMID: 32640300
  24. Fattahi, S.; Nikbakhsh, N.; Ranaei, M.; Sabour, D.; Akhavan-Niaki, H. Association of sonic hedgehog signaling pathway genes IHH, BOC, RAB23a and MIR195-5p, MIR509-3-5p, MIR6738-3p with gastric cancer stage. Sci. Rep., 2021, 11(1), 1-12. PMID: 33414495
  25. Rahimi, H.R.; Mojarrad, M.; Moghbeli, M. MicroRNA-96: A therapeutic and diagnostic tumor marker. Iran. J. Basic Med. Sci., 2022, 25(1), 3-13. PMID: 35656454
  26. Varamo, C.; Occelli, M.; Vivenza, D.; Merlano, M.; Lo Nigro, C. MicroRNAs role as potential biomarkers and key regulators in melanoma. Genes Chromosomes Cancer, 2017, 56(1), 3-10. doi: 10.1002/gcc.22402 PMID: 27561079
  27. Mione, M.; Bosserhoff, A. MicroRNAs in melanocyte and melanoma biology. Pigment Cell Melanoma Res., 2015, 28(3), 340-354. doi: 10.1111/pcmr.12346 PMID: 25515738
  28. Binder, H.; Schmidt, M.; Loeffler-Wirth, H.; Mortensen, L.S.; Kunz, M. Melanoma single-cell biology in experimental and clinical settings. J. Clin. Med., 2021, 10(3), 506. doi: 10.3390/jcm10030506 PMID: 33535416
  29. McInnes, M.D.F.; Moher, D.; Thombs, B.D.; McGrath, T.A.; Bossuyt, P.M.; Clifford, T.; Cohen, J.F.; Deeks, J.J.; Gatsonis, C.; Hooft, L.; Hunt, H.A.; Hyde, C.J.; Korevaar, D.A.; Leeflang, M.M.G.; Macaskill, P.; Reitsma, J.B.; Rodin, R.; Rutjes, A.W.S.; Salameh, J.P.; Stevens, A.; Takwoingi, Y.; Tonelli, M.; Weeks, L.; Whiting, P.; Willis, B.H. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. JAMA, 2018, 319(4), 388-396. doi: 10.1001/jama.2017.19163 PMID: 29362800
  30. Armand-Labit, V.; Meyer, N.; Casanova, A.; Bonnabau, H.; Platzer, V.; Tournier, E.; Sansas, B.; Verdun, S.; Thouvenot, B.; Hilselberger, B.; Doncescu, A.; Lamant, L.; Lacroix-Triki, M.; Favre, G.; Pradines, A. Identification of a circulating microRNA profile as a biomarker of metastatic cutaneous melanoma. Acta Derm. Venereol., 2016, 96(1), 29-34. doi: 10.2340/00015555-2156 PMID: 26039581
  31. Guo, S.; Guo, W.; Li, S.; Dai, W.; Zhang, N.; Zhao, T.; Wang, H.; Ma, J.; Yi, X.; Ge, R.; Wang, G.; Gao, T.; Li, C. Serum miR-16: A potential biomarker for predicting melanoma prognosis. J. Invest. Dermatol., 2016, 136(5), 985-993. doi: 10.1016/j.jid.2015.12.041 PMID: 26829037
  32. Stark, M.S.; Klein, K.; Weide, B.; Haydu, L.E.; Pflugfelder, A.; Tang, Y.H.; Palmer, J.M.; Whiteman, D.C.; Scolyer, R.A.; Mann, G.J.; Thompson, J.F.; Long, G.V.; Barbour, A.P.; Soyer, H.P.; Garbe, C.; Herington, A.; Pollock, P.M.; Hayward, N.K. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: A microRNA expression analysis. EBioMedicine, 2015, 2(7), 671-680. doi: 10.1016/j.ebiom.2015.05.011 PMID: 26288839
  33. Ono, S.; Oyama, T.; Lam, S.; Chong, K.; Foshag, L.J.; Hoon, D.S.B. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget, 2015, 6(9), 7053-7064. doi: 10.18632/oncotarget.3142 PMID: 25749524
  34. Tengda, L.; Shuping, L.; Mingli, G.; Jie, G.; Yun, L.; Weiwei, Z.; Anmei, D. Serum exosomal microRNAs as potent circulating biomarkers for melanoma. Melanoma Res., 2018, 28(4), 295-303. doi: 10.1097/CMR.0000000000000450 PMID: 29750752
  35. Bai, M.; Zhang, H.; Si, L.; Yu, N.; Zeng, A.; Zhao, R. Upregulation of serum miR-10b is associated with poor prognosis in patients with melanoma. J. Cancer, 2017, 8(13), 2487-2491. doi: 10.7150/jca.18824 PMID: 28900486
  36. Fogli, S.; Polini, B.; Carpi, S.; Pardini, B.; Naccarati, A.; Dubbini, N.; Lanza, M.; Breschi, M.C.; Romanini, A.; Nieri, P. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. Tumour Biol., 2017, 39(5) doi: 10.1177/1010428317701646 PMID: 28466785
  37. Leidinger, P.; Keller, A.; Borries, A.; Reichrath, J.; Rass, K.; Jager, S.U.; Lenhof, H.P.; Meese, E. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer, 2010, 10(1), 262. doi: 10.1186/1471-2407-10-262 PMID: 20529253
  38. Van Laar, R.; Lincoln, M.; Van Laar, B. Development and validation of a plasma-based melanoma biomarker suitable for clinical use. Br. J. Cancer, 2018, 118(6), 857-866. doi: 10.1038/bjc.2017.477 PMID: 29360813
  39. Ferracin, M.; Veronese, A.; Negrini, M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev. Mol. Diagn., 2010, 10(3), 297-308. doi: 10.1586/erm.10.11 PMID: 20370587
  40. Begg, C.B.; Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994, 50(4), 1088-1101. doi: 10.2307/2533446 PMID: 7786990
  41. Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997, 315(7109), 629-634. doi: 10.1136/bmj.315.7109.629 PMID: 9310563
  42. Singh, S.R.K.; Malapati, S.J.; Kumar, R.; Willner, C.; Wang, D. NCDB Analysis of Melanoma 2004–2015: Epidemiology and outcomes by subtype, sociodemographic factors impacting clinical presentation, and real-world survival benefit of immunotherapy approval. Cancers, 2021, 13(6), 1455. doi: 10.3390/cancers13061455 PMID: 33810182
  43. Brown, M.C.; Kindred, C. Physiology of Skin Pigmentation. In: Ethnic skin and hair and other cultural considerations; Springer, 2021; pp. 35-40. doi: 10.1007/978-3-030-64830-5_4
  44. Bhattacharya, B.; Chauhan, D.; Singh, A.K.; Chatterjee, M. Melanin based classification of skin types and their susceptibility to UV-induced cancer. In: Skin Cancer: Pathogenesis and Diagnosis; Springer, 2021; pp. 41-67. doi: 10.1007/978-981-16-0364-8_3
  45. Liu, D. Tumors and cancers: Skin–Soft Tissue–Bone–Urogenitals; CRC Press, 2017.
  46. Simon, A.; Kourie, H.R.; Kerger, J. Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review. Chin. J. Cancer, 2017, 36(1), 10. doi: 10.1186/s40880-017-0179-6 PMID: 28086948
  47. Bravo-Vázquez, L.A.; Frías-Reid, N.; Ramos-Delgado, A.G.; Osorio-Pérez, S.M.; Zlotnik-Chávez, H.R.; Pathak, S.; Banerjee, A.; Bandyopadhyay, A.; Duttaroy, A.K.; Paul, S. MicroRNAs and long non-coding RNAs in pancreatic cancer: From epigenetics to potential clinical applications. Transl. Oncol., 2023, 27, 101579. doi: 10.1016/j.tranon.2022.101579 PMID: 36332600
  48. Mirzaei, H.; Gholamin, S.; Shahidsales, S.; Sahebkar, A.; Jaafari, M.R.; Mirzaei, H.R.; Hassanian, S.M.; Avan, A. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur. J. Cancer, 2016, 53, 25-32. doi: 10.1016/j.ejca.2015.10.009 PMID: 26693896
  49. Gajos-Michniewicz, A.; Czyz, M. Role of miRNAs in melanoma metastasis. Cancers, 2019, 11(3), 326. doi: 10.3390/cancers11030326 PMID: 30866509
  50. Li, W.; Sanki, A.; Karim, R.Z.; Thompson, J.F.; Soon Lee, C.; Zhuang, L.; McCarthy, S.W.; Scolyer, R.A. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology, 2006, 38(4), 287-301. doi: 10.1080/00313020600817951 PMID: 16916716
  51. Wang, J.; Yu, F.; Jia, X.; Iwanowycz, S.; Wang, Y.; Huang, S.; Ai, W.; Fan, D. MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int. J. Cancer, 2015, 136(6), E602-E613. doi: 10.1002/ijc.29151 PMID: 25143000
  52. El Hajj, P.; Gilot, D.; Migault, M.; Theunis, A.; van Kempen, L.C.; Salés, F.; Fayyad-Kazan, H.; Badran, B.; Larsimont, D.; Awada, A.; Bachelot, L.; Galibert, M-D.; Ghanem, G.; Journe, F. SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma. Br. J. Cancer, 2015, 113(1), 91-98. doi: 10.1038/bjc.2015.194 PMID: 26068396
  53. Zhou, X.; Yan, T.; Huang, C.; Xu, Z.; Wang, L.; Jiang, E.; Wang, H.; Chen, Y.; Liu, K.; Shao, Z.; Shang, Z. Melanoma cell-secreted exosomal miR-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway. J. Exp. Clin. Cancer Res., 2018, 37(1), 242. doi: 10.1186/s13046-018-0911-3 PMID: 30285793
  54. Jiang, L.; Lv, X.; Li, J.; Li, J.; Li, X.; Li, W.; Li, Y. The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma. Acta Histochem., 2012, 114(6), 582-588. doi: 10.1016/j.acthis.2011.11.001 PMID: 22130252
  55. Satzger, I.; Mattern, A.; Kuettler, U.; Weinspach, D.; Niebuhr, M.; Kapp, A.; Gutzmer, R. microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. Exp. Dermatol., 2012, 21(7), 509-514. doi: 10.1111/j.1600-0625.2012.01510.x PMID: 22716245
  56. MicroRNA heterogeneity in melanoma progression. In: Seminars in cancer biology; Thyagarajan, A.; Tsai, K.Y.; Sahu, R.P., Eds.; Elsevier, 2019.
  57. Dar, A.A.; Majid, S.; de Semir, D.; Nosrati, M.; Bezrookove, V.; Kashani-Sabet, M. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J. Biol. Chem., 2011, 286(19), 16606-16614. doi: 10.1074/jbc.M111.227611 PMID: 21454583
  58. Aalami, A.H.; Aalami, F.; Sahebkar, A. Gastric cancer and circulating microRNAs: An updated systematic review and diagnostic meta-analysis. Curr. Med. Chem., 2023. PMID: 36411580
  59. Ye, Q.; Wang, J.; Xu, D.; Liu, Y.; Zhang, D.; Ye, J.; Li, H. Diagnostic performance of urine and blood microRNAs for bladder cancer: A meta-analysis. Expert Rev. Anticancer Ther., 2022, 22(12), 1357-1369. doi: 10.1080/14737140.2022.2147511 PMID: 36374119
  60. Zafari, N.; Bahramy, A.; Majidi Zolbin, M.; Emadi Allahyari, S.; Farazi, E.; Hassannejad, Z.; Yekaninejad, M.S. microRNAs as novel diagnostic biomarkers in endometriosis patients: A systematic review and meta-analysis. Expert Rev. Mol. Diagn., 2022, 22(4), 479-495. doi: 10.1080/14737159.2021.1960508 PMID: 34304687
  61. Fathi, S.; Guessous, F.; Karkouri, M. Diagnostic value of potential microRNAs in CRC: A meta-analysis. MicroRNA, 2022, 11(3), 190-205. doi: 10.2174/2211536611666220523103316 PMID: 35616664
  62. Durante, G; Broseghini, E; Comito, F; Naddeo, M; Milani, M; Salamon, I; Campione, E; Dika, E; Ferracin, M Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer. Exp. Rev. Mol. Diag., 2022. doi: 10.1080/14737159.2022.2049243

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2024